Adaptimmune

TRANSFORMING T CELL THERAPY

WHO WE ARE

Adaptimmune is a fully integrated, cell therapy company focused on the development of novel cancer immunotherapy products. We are leading the field of engineered TCRs with our SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform, developing therapies with the right target, the right affinity and the right specificity to treat solid tumors.

This TCR platform enables the engineering of T-cells to target and destroy cancer, including solid tumors that are not treatable by other existing immunotherapies. Adaptimmune has a pipeline of wholly owned targets including MAGE-A4, MAGE-A10, and AFP against several solid tumor types.

With its NY-ESO SPEAR T-cell, Adaptimmune was the first company to have shown efficacy and safety with a TCR therapy in a solid tumor. In September 2017, GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune's NY-ESO SPEAR T-cell therapy program. Transition of this program to GSK is ongoing.

Adaptimmune is located in Philadelphia, USA, and Oxfordshire, U.K.

For more information, please visit www.adaptimmune.com.